Phase II trial of spirogermanium and vindesine in malignant glioma.
Phase II trial of spirogermanium and vindesine in malignant glioma.
复制标题
螺锗和长春地辛治疗恶性神经胶质瘤的 II 期试验。
DOI：
10.1097/00000421-198902000-00002
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Marsh,JC
中科院分区：
文献类型：
--
作者：
Alavi,JB;Schoenfeld,D;Skeel,RT;Kirkwood,R;Tsung,L;Marsh,JC
在东部肿瘤协作组（ECOG）试验中治疗了54例复发性恶性胶质瘤成人。所有人都曾接受过放射治疗，70%的人曾接受过化疗。他们被分配到长春地辛3 mg/m2每周或螺锗80 mg/m2每周三次，递增至120 mg/m2。长春地辛的反应为4%，螺锗的反应为8%。对于仅具有临床改善的患者，反应持续时间为53天，但是对于通过计算机断层扫描（CT）实现肿瘤大小减小> 50%的两名患者，反应持续时间> 151天和> 1066天。长春地辛的毒性为血液毒性，螺锗的毒性为神经毒性。这两种药物似乎都没有足够的疗效，以保证在以前治疗过的胶质瘤患者中进行进一步的试验。
Fifty-four adults with recurrent malignant glioma were treated on an Eastern Cooperative Oncology Group (ECOG) trial. All had previous radiation therapy, and 70% had previous chemotherapy. They were assigned to either vindesine 3 mg/m 2 weekly or spirogermanium 80 mg/m 2 three times weekly with escalation to 120 mg/m 2. The response was 4% to vindesine, and 8% to spirogermanium. The duration of response was 53 days for a patient who had clinical improvement only, but> 151 days and> 1066 days for two patients who had achieved a> 50% reduction in tumor size by computed tomography (CT). The toxicities were hematologic for vindesine and neurologic for spirogermanium. Neither agent seems to have sufficient efficacy to warrant further trials in previously treated glioma patients.